» Articles » PMID: 9738049

Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 Against Opportunistic Filamentous and Dimorphic Fungi and Yeasts

Overview
Specialty Microbiology
Date 1998 Sep 17
PMID 9738049
Citations 173
Authors
Affiliations
Soon will be listed here.
Abstract

The in vitro antifungal activities of SCH56592, MK-0991, and LY303366 against 83 isolates of Acremonium strictum, Aspergillus flavus, Aspergillus fumigatus, Aspergillus terreus, Bipolaris spp., Blastomyces dermatitidis, Cladophialophora bantiana, Fusarium oxysporum, Fusarium solani, Histoplasma capsulatum, Phialophora spp., Pseudallescheria boydii, Rhizopus arrhizus, Scedosporium prolificans, and Sporothrix schenckii were compared. The in vitro activities of these agents against 104 isolates of yeast pathogens of Candida spp., Cryptococcus neoformans, and Trichosporon beigelii were also compared. MICs were determined by following a procedure under evaluation by the National Committee for Clinical Laboratory Standards (NCCLS) for broth microdilution testing of the filamentous fungi (visual MICs) and the NCCLS M27-A broth microdilution method for yeasts (both visual and turbidimetric MICs). The in vitro fungicidal activity of SCH56592 was superior (minimum fungicidal concentrations [MFCs], 0.25 to 4 microgram/ml for 7 of 18 species tested) to those of MK-0991 and LY303366 (MFCs, 8 to >16 microgram/ml for all species tested) for the molds tested, but the echinocandins had a broader spectrum of fungicidal activity (MFCs at which 90% of strains are inhibited [MFC90s], 0.5 to 4 microgram/ml for 6 of 9 species tested) than SCH56592 (MFC90s, 0.25 to 8 microgram/ml for 4 of 9 species tested) against most of the yeasts tested. Neither echinocandin had in vitro activity (MICs, >16 microgram/ml) against C. neoformans and T. beigelii, while the SCH56592 MICs ranged from 0.12 to 1.0 microgram/ml for these two species. The MICs of the three agents for the other species ranged from <0.03 to 4 microgram/ml. These results suggest that these new agents have broad-spectrum activities in vitro; their effectiveness in the treatment of human mycoses is to be determined.

Citing Articles

Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review.

Liang M, Xu J, Luo Y, Qu J Ann Med. 2024; 56(1):2396570.

PMID: 39221718 PMC: 11370679. DOI: 10.1080/07853890.2024.2396570.


Genotypic diversity, virulence, and molecular genetic tools in .

Sepulveda V, Goldman W, Matute D Microbiol Mol Biol Rev. 2024; 88(2):e0007623.

PMID: 38819148 PMC: 11332355. DOI: 10.1128/mmbr.00076-23.


Fungal brain abscesses caused by species.

Ibrahim H, Alfishawy M, Ali A, Maksod S, Khorshed M, Rady H Egypt J Intern Med. 2023; 35(1):5.

PMID: 36741047 PMC: 9884595. DOI: 10.1186/s43162-022-00183-z.


Serine/Threonine Phosphatase Calcineurin Orchestrates the Intrinsic Resistance to Micafungin in the Human-Pathogenic Fungus Mucor circinelloides.

Garcia A, Huh E, Lee S Antimicrob Agents Chemother. 2023; 67(2):e0068622.

PMID: 36688672 PMC: 9933632. DOI: 10.1128/aac.00686-22.


Design, Synthesis, Characterization, and Analysis of Antimicrobial Property of Novel Benzophenone Fused Azetidinone Derivatives through In Vitro and In Silico Approach.

Venkataravanappa L, Jyothi M, Khamees H, Silina E, Stupin V, Achar R Curr Issues Mol Biol. 2023; 45(1):92-109.

PMID: 36661493 PMC: 9857151. DOI: 10.3390/cimb45010007.


References
1.
Graybill J, Najvar L, Luther M, Fothergill A . Treatment of murine disseminated candidiasis with L-743,872. Antimicrob Agents Chemother. 1997; 41(8):1775-7. PMC: 164003. DOI: 10.1128/AAC.41.8.1775. View

2.
Jarvis W . Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis. 1995; 20(6):1526-30. DOI: 10.1093/clinids/20.6.1526. View

3.
Kauffman C, Carver P . Antifungal agents in the 1990s. Current status and future developments. Drugs. 1997; 53(4):539-49. DOI: 10.2165/00003495-199753040-00001. View

4.
Law D, Moore C, Denning D . Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother. 1997; 41(10):2310-1. PMC: 164118. DOI: 10.1128/AAC.41.10.2310. View

5.
Oakley K, Morrissey G, Denning D . Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother. 1997; 41(7):1504-7. PMC: 163948. DOI: 10.1128/AAC.41.7.1504. View